Peptide fusion with or encapsulation of nucleic acid by the truncated capsid protein of the hepatitis E virus (HEV) can cause specific antigenic responses in the host.
A portion of the hepatitis E virus (HEV), the truncated capsid protein, is able to self-assemble into a virus like particle (VLP) that contains no HEV genomic RNA. The VLP can be modified by deletions or modifications to the truncated capsid protein and by itself stimulates response to HEV.
Researchers at the University of California, Davis have discovered that fusion of the HEV capsid protein with a heterologous peptide can cause specific antigenic responses in the host. Furthermore, the VLP can also encapsulate nucleic acid, permitting another method for stimulating antigenic responses in the host. Specific lysis by CTL effect in response to HIV epitopes was evaluated by spleen, mesenteric lymph nodes and Peyer’s patch cells from immunized animals. Synergistic effects are possible when the capsid is fused to a peptide while also encapsulating a nucleic acid or other drug.
|United States Of America||Issued Patent||9,637,524||05/02/2017||2008-639|
|United States Of America||Issued Patent||8,906,862||12/09/2014||2008-639|
|United States Of America||Issued Patent||8,906,863||12/09/2014||2008-639|
hepatitis E virus, HEV, HEV capsid protein, antigenic response, virus like particle, VLP, heterologous peptide fusion